2006 – Present
Press releases and published papers for each grant are available on the Foundation’s site. Follow-on funding is additional funding awarded at a later stage.

TGFBR2 knockout, TROP2-targeting CAR NK cells in combination with zolbetuximab for gastric cancer with peritoneal metastases
Download the press release (PDF) →
Clinical translation of a novel dual-targeted CAR T cell therapy for gastroesophageal cancer metastases
Download the press release (PDF) →
Validation of druggable targets in gastroesophageal cancers to optimize response to immune checkpoint blockade
Download the press release (PDF) →
Modified Trefoil Factor Family 2 (TFF2-MSA) as a novel therapy for gastroesophageal cancer
Download the press release (PDF) →
New targets for molecular glue degraders in gastroesophageal cancer
Download the press release (PDF) →
Development of a personalized dendritic cell/organoid based vaccine for the treatment of gastric cancer
Download the press release (PDF) →
Targeting cancer stem cell populations by dual inhibition of Notch and Wnt pathways
Download the press release (PDF) →
Targeting mitochondrial resistance to apoptosis after neoadjuvant therapy in esophageal adenocarcinoma
Download the press release (PDF) →
Targeting the novel MT +TIP variant CLIP-170S to reverse taxane resistance in gastroesophageal cancer
Download the press release (PDF) →
Chimeric antigen receptor (CAR) macrophages for the treatment of gastroesophageal cancer
Download the press release (PDF) →
Dual-targeted CAR T cell strategy to enhance the durability of adoptive cellular therapy for gastric/esophageal cancers
Download the press release (PDF) →
Manipulating redox metabolism with pharmacologic ascorbate and superoxide dismutase mimetics to enhance chemoradiation for locally advanced esophageal adenocarcinoma
Download the press release (PDF) →
Harnessing DNA damage response to enhance immunotherapy response in XRCC1 deficient stomach cancer
Download the press release (PDF) →
Defining gene dependencies in whole-genome doubled esophageal adenocarcinomas
Download the press release (PDF) →
Defining the phenotype and cancer penetrance of CTNNA1 loss-of-function germline variants
Download the press release (PDF) →
Personalized drug development in gastroesophageal cancer with high-throughput drug screening of tumor-derived organoids

Therapeutic potential of DNA damage response inhibitors in gastroesophageal cancers
Download the press release (PDF) →
Oncogenic TGFβ signaling as a new molecular paradigm and therapeutic vulnerability in esophageal cancer

Master transcription factor TP63 governs immune evasion of esophageal squamous cell carcinoma
Download the press release (PDF) →
Create tumor organoids (miniaturized and simplified versions of organs) that replicate the tumor in a petri dish
Download the press release (PDF) →
Study the effectiveness of CAR-T therapy as a treatment for gastroesophageal cancers

Master transcription factor circuitry in esophageal cancer

Human esophageal myofibroblast paracrine regulation of esophageal inflammation and carcinogenesis

Screening study to better identify people at the highest risk for the most common form of esophageal cancer

Targeting MK2 for treatment of gastric cancer

The role of novel RHO pathway genomic alterations in diffuse gastric cancer

Elucidating protective mechanisms against gastric cancer

Evaluating the feasibility of a molecular cytology approach for management of patients with Barrett’s esophagus

Role of the novel IL-1 family member IL-33 in the gastric metaplasia–carcinoma sequence

Identification of new drugs for the treatment and prevention of diffuse gastric cancer using a high-throughput compound screening approach

Targeting gastroesophageal cancer through dual transcription inhibitors

Next-generation sequencing to evaluate transcriptomic changes associated with H. pylori infection and gastric cancer carcinogenesis

Investigations into the genes and genetic differences which are drivers of esophageal cancer

Early Onset and Familial Gastric Cancer Registry